Antiangiogenic agents in the management of non-small cell lung cancer Where do we stand now and where are we headed?

被引：60

作者：

Aggarwal, Charu ^{[2
]}

Somaiah, Neeta ^{[1
]}

Simon, George R. ^{[1
]}

机构：

[1] Med Univ S Carolina, Dept Med, Div Hematol Oncol, Charleston, SC 29425 USA

[2] Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA

来源：

CANCER BIOLOGY & THERAPY | 2012年 / 13卷 / 05期

关键词：

ENDOTHELIAL GROWTH-FACTOR; TRIPLE ANGIOKINASE INHIBITOR; TYROSINE KINASE INHIBITOR; RANDOMIZED PHASE-III; DOUBLE-BLIND; 1ST-LINE THERAPY; FACTOR RECEPTOR; OPEN-LABEL; MAINTENANCE BEVACIZUMAB; TREATMENT RATIONALE;

D O I：

10.4161/cbt.19594

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Several therapies targeting angiogenesis are currently in development for non-small cell lung cancer (NSCLC). This review discusses results of recent clinical trials evaluating chemotherapy plus antiangiogenic therapy for NSCLC. Bevacizumab, an anti-VEGF antibody, is currently approved for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. Completed phase III trials evaluating bevacizumab plus chemotherapy have shown prolonged progression-free survival; however, not all trials showed significant improvement in overall survival (OS). Phase III trials of the tyrosine kinase inhibitors (TKIs) vandetanib and sorafenib and the vascular disrupting agent ASA404 also failed to improve OS compared with chemotherapy alone. Clinical trials are ongoing involving several new antiangiogenic therapies, including ramucirumab, aflibercept, cediranib, nintedanib (BIBF 1120), sunitinib, pazopanib, brivanib, ABT869, axitinib, ABT-751 and NPI-2358; several of these agents have shown promising phase I/II results. Results from recently completed and ongoing phase III trials will determine if these newer antiangiogenic agents will be incorporated into clinical practice.

引用

页码：247 / 263

页数：17

共 88 条

[41] Antiangiogenic therapy: A universal chemosensitization strategy for cancer? [J].

Kerbel, Robert S. .

SCIENCE, 2006, 312 (5777) :1171-1175

[42] Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity [J].

Kumar, Rakesh ;

Knick, Victoria B. ;

Rudolph, Sharon K. ;

Johnson, Jennifer H. ;

Crosby, Renae M. ;

Crouthamel, Ming-Chih ;

Hopper, Teresa M. ;

Miller, Charles G. ;

Harrington, Laura E. ;

Onori, James A. ;

Mullin, Robert J. ;

Gilmer, Tona M. ;

Truesdale, Anne T. ;

Epperly, Andrea H. ;

Boloor, Amogh ;

Stafford, Jeffrey A. ;

Luttrell, Deirdre K. ;

Cheung, Mui .

MOLECULAR CANCER THERAPEUTICS, 2007, 6 (07) :2012-2021

[43] Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non-Small-Cell Lung Cancer [J].

Lara, Primo N., Jr. ;

Douillard, Jean-Yves ;

Nakagawa, Kazuhiko ;

von Pawel, Joachim ;

McKeage, Mark J. ;

Albert, Istvan ;

Losonczy, Gyoergy ;

Reck, Martin ;

Heo, Dae-Seog ;

Fan, Xiaolin ;

Fandi, Abderrahim ;

Scagliotti, Giorgio .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) :2965-2971

[44] Phase I trial CCL21 gene modified dendritic cells in non-small cell lung cancer [J].

Lee, J. M. ;

Garon, E. B. ;

Baratelli, F. ;

Schaue, D. ;

Pak, P. S. ;

Wallace, W. D. ;

Suh, R. ;

Abtin, F. ;

Zeng, G. ;

Dubinett, S. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[45] Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study [J].

Leighl, N. B. ;

Bennouna, J. ;

Yi, J. ;

Moore, N. ;

Hambleton, J. ;

Hurwitz, H. .

BRITISH JOURNAL OF CANCER, 2011, 104 (03) :413-418

[46] Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL) [J].

Leighl, Natasha B. ;

Zatloukal, Petr ;

Mezger, Joerg ;

Ramlau, Rodryg ;

Moore, Nicola ;

Reck, Martin ;

Manegold, Christian .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) :1970-1976

[47] A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung [J].

Leighl, Natasha B. ;

Raez, Luis E. ;

Besse, Benjamin ;

Rosen, Peter J. ;

Barlesi, Fabrice ;

Massarelli, E. ;

Gabrail, Nashat ;

Hart, Lowell L. ;

Albain, Kathy S. ;

Berkowitz, Lloyd ;

Melnyk, Ostap ;

Shepherd, Frances A. ;

Sternas, Lars ;

Ackerman, Judie ;

Shun, Zhenming ;

Miller, Vincent A. ;

Herbst, Roy S. .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (07) :1054-1059

[48] Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer [J].

McKeage, M. J. ;

Von Pawel, J. ;

Reck, M. ;

Jameson, M. B. ;

Rosenthal, M. A. ;

Sullivan, R. ;

Gibbs, D. ;

Mainwaring, P. N. ;

Serke, M. ;

Lafitte, J-J ;

Chouaid, C. ;

Freitag, L. ;

Quoix, E. .

BRITISH JOURNAL OF CANCER, 2008, 99 (12) :2006-2012

[49] Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800 mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer [J].

McKeage, Mark J. ;

Reck, Martin ;

Jameson, Michael B. ;

Rosenthal, Mark A. ;

Gibbs, David ;

Mainwaring, Paul N. ;

Freitag, Lutz ;

Sullivan, Richard ;

Von Pawel, Joachim .

LUNG CANCER, 2009, 65 (02) :192-197

[50] Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors [J].

Mekhail, Tarek ;

Masson, Eric ;

Fischer, Bruce S. ;

Gong, Jiachang ;

Iyer, Ramaswamy ;

Gan, Jinping ;

Pursley, Janice ;

Patricia, Daniel ;

Williams, Daphne ;

Ganapathi, Ram .

DRUG METABOLISM AND DISPOSITION, 2010, 38 (11) :1962-1966

← 1 2 3 4 5 6 7 8 9 →